Skip to main content

Table 1 Frequency of reported antibodies to infliximab and adalimumab in various inflammatory diseases

From: The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review

Inflammatory disease ATIs, percentage AAAs, percentage References
Rheumatoid arthritis 8-52 12-44 [29]
Crohn disease 14-75 2.6-17 [1017]
Juvenile idiopathic arthritis NA 17 [18]
Ankylosing spondylitis 29 31 [19, 20]
Psoriatic arthritis NA 18 [21]
Psoriasis NA 45 [22]
  1. AAA, anti-adalimumab antibody; ATI, antibody to infliximab; NA, not applicable.